November 9, 2015
Lilly’s ixekizumab shows improvements in signs and symptoms of their disease when compared to placebo
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…